PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (VTRS) (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the ...
"We are pleased with the profile our investigational XULANE LO low dose patch demonstrated in this Phase 3 study," said Viatris Chief R&D Officer Philippe Martin. "The data underscores our confidence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback